Memorial Sloan Kettering Cancer Center
ASCO® 2023 Insights: "PERSIST-2 Landmark OS Analysis - Spleen Volume Reduction Predicts OS in Myelofibrosis Pts on Pacritinib, But Not Best Available Therapy"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Helen Ajufo
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Helen Ajufo
Comments 0
Login to view comments.
Click here to Login